Mabpharm Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Hao Wang
Chief executive officer
CN¥5.6m
Total compensation
| CEO salary percentage | 19.1% |
| CEO tenure | 6.4yrs |
| CEO ownership | n/a |
| Management average tenure | 6.4yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
Investors Don't See Light At End Of Mabpharm Limited's (HKG:2181) Tunnel
Dec 22
Shareholders May Be A Bit More Conservative With Mabpharm Limited's (HKG:2181) CEO Compensation For Now
Jun 14More Unpleasant Surprises Could Be In Store For Mabpharm Limited's (HKG:2181) Shares After Tumbling 41%
Jan 24Mabpharm (HKG:2181) Is Making Moderate Use Of Debt
Oct 20Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation
Jan 18Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation
Oct 07Here's Why We're Not Too Worried About Mabpharm's (HKG:2181) Cash Burn Situation
Apr 28Did You Miss Mabpharm's (HKG:2181) 14% Share Price Gain?
Mar 03We're Not Very Worried About Mabpharm's (HKG:2181) Cash Burn Rate
Jan 27
Do Insiders Own Lots Of Shares In Mabpharm Limited (HKG:2181)?
Dec 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -CN¥207m |
| Mar 31 2024 | n/a | n/a | -CN¥208m |
| Dec 31 2023 | CN¥6m | CN¥1m | -CN¥209m |
| Sep 30 2023 | n/a | n/a | -CN¥202m |
| Jun 30 2023 | n/a | n/a | -CN¥194m |
| Mar 31 2023 | n/a | n/a | -CN¥202m |
| Dec 31 2022 | CN¥3m | CN¥1m | -CN¥211m |
| Sep 30 2022 | n/a | n/a | -CN¥237m |
| Jun 30 2022 | n/a | n/a | -CN¥263m |
| Mar 31 2022 | n/a | n/a | -CN¥278m |
| Dec 31 2021 | CN¥5m | CN¥1m | -CN¥292m |
Compensation vs Market: Hao's total compensation ($USD763.22K) is above average for companies of similar size in the Hong Kong market ($USD230.17K).
Compensation vs Earnings: Hao's compensation has increased whilst the company is unprofitable.
CEO
Hao Wang (55 yo)
6.4yrs
Tenure
CN¥5,596,000
Compensation
Dr. Hao Wang serves as Chief Executive Officer and Executive Director at Mabpharm Limited since October 28, 2020 and July 20, 2018 respectively and also serves as Chief Scientist since August 2018. Dr. Wan...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Scientist | 6.4yrs | CN¥5.60m | no data | |
| VP & Executive Director | no data | CN¥1.54m | no data | |
| VP & Executive Director | 1.2yrs | CN¥70.00k | no data | |
| VP & Executive Director | less than a year | CN¥445.00k | no data | |
| VP, Joint Company Secretary & Executive Director | 6.4yrs | CN¥1.58m | no data | |
| Vice President | 6.4yrs | CN¥1.40m | no data | |
| Joint Company Secretary | no data | no data | no data |
6.4yrs
Average Tenure
49yo
Average Age
Experienced Management: 2181's management team is seasoned and experienced (6.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Scientist | 6.5yrs | CN¥5.60m | no data | |
| VP & Executive Director | 4.3yrs | CN¥1.54m | no data | |
| VP & Executive Director | 1.2yrs | CN¥70.00k | no data | |
| VP & Executive Director | 1.2yrs | CN¥445.00k | no data | |
| VP, Joint Company Secretary & Executive Director | 6.5yrs | CN¥1.58m | no data | |
| Non-Executive Chairman | 6.5yrs | no data | no data | |
| Independent Non-Executive Director | 6.4yrs | CN¥108.00k | no data | |
| Independent Non-Executive Director | 6.4yrs | CN¥108.00k | no data | |
| Independent Non-Executive Director | 2.6yrs | CN¥108.00k | no data | |
| Non-Executive Director | less than a year | no data | no data | |
| Independent Non-Executive Director | less than a year | no data | no data |
4.3yrs
Average Tenure
51yo
Average Age
Experienced Board: 2181's board of directors are considered experienced (4.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/09 20:02 |
| End of Day Share Price | 2025/01/09 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Mabpharm Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yue-Kwong Lui | Jefferies LLC |